Massachusetts General Hospital Psychopharmacology and Neurotherapeutics
- 2nd Edition - September 2, 2024
- Imprint: Elsevier
- Editors: Theodore A. Stern, Joan A. Camprodon, Maurizio Fava
- Language: English
- Paperback ISBN:9 7 8 - 0 - 4 4 3 - 1 1 9 7 2 - 9
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 1 1 9 7 3 - 6
Offering user-friendly, authoritative guidance on cutting-edge psychopharmacologic and somatic treatments for psychiatric and neurologic conditions, Massachusetts General Hospital… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteOffering user-friendly, authoritative guidance on cutting-edge psychopharmacologic and somatic treatments for psychiatric and neurologic conditions, Massachusetts General Hospital Psychopharmacology and Neurotherapeutics, 2nd Edition, helps you put today's best approaches to work for your patients. Composed of topical chapters primarily from the third edition of Stern et al.’s Massachusetts General Hospital Comprehensive Clinical Psychiatry, this fully revised resource focuses on current psychotropic treatments, electroconvulsive therapy, and neurotherapeutics, making it an ideal quick reference for psychiatrists, psychologists, internists, and nurse practitioners.
- Brings you up-to-date information on key topics in the field, including the application of anticonvulsants, anxiolytics, mood stabilizers, and psychostimulants; drug–drug interactions; side effects; treatment adherence; and more
- Includes detailed coverage of antidepressants, antipsychotics, and antianxiety medications, as well as advances in caring for patients with treatment-resistant depression and new legal considerations when prescribing psychotropics
- Covers recent progress on the use of neurotherapeutic interventions, such as transcranial magnetic stimulation, vagal nerve stimulation, and deep brain stimulation
- Contains a new chapter on the pharmacotherapy of movement disorders (derived from Stern et al.’s MGH Handbook of General Hospital Psychiatry, 8th Edition)
- Features a user-friendly, highly templated format with abundant boxed summaries, bulleted points, case histories, algorithms, updated references, and suggested readings
- Offers updated DSM-5-TR criteria alongside peerless, hands-on advice from members of the esteemed MGH Department of Psychiatry
- An eBook version is included with purchase. The eBook allows you to access all of the text, figures, and references, with the ability to search, customize your content, make notes and highlights, and have content read aloud. Additional digital ancillary content may publish up to 6 weeks following the publication date
Practicing psychiatrists, psychologists, internists, and nurse practitioners
- Cover image
- Title page
- Table of Contents
- Activate your eBook today!
- Copyright
- Preface
- Contributors
- 1. Psychiatric Neuroscience: Incorporating Pathophysiology into Clinical Case Formulation
- OVERVIEW
- PSYCHIATRIC DIAGNOSIS: BIOMARKERS AND BIOLOGICAL VALIDITY
- METHODS IN PSYCHIATRIC NEUROSCIENCE
- BIOLOGICAL CASE FORMULATION: NEUROSCIENTIFIC CONTENT AND PROCESS
- GENES, ENVIRONMENT, AND EPIGENETICS
- OVERVIEW OF THE STRUCTURE OF THE CENTRAL NERVOUS SYSTEM
- CELLULAR DIVERSITY IN THE BRAIN: NEURONS AND GLIA
- THE STRUCTURE OF THE SYNAPSE
- A REVIEW OF CLINICALLY RELEVANT NEUROTRANSMITTER SYSTEMS
- CONCLUSION
- REFERENCES
- 2. Treatment Adherence
- OVERVIEW
- EPIDEMIOLOGY OF ADHERENCE
- CLINICAL AND ECONOMIC IMPACT OF NON-ADHERENCE
- RISK FACTORS FOR NON-ADHERENCE
- ASSESSING ADHERENCE
- INTEGRATING ADHERENCE INTO THE TREATMENT COURSE
- PROBLEM-SOLVING BARRIERS TO ADHERENCE
- FUTURE DIRECTIONS
- CONCLUSION
- References
- 3. Pharmacological Approaches to Depression and Treatment-Resistant Depression
- OVERVIEW
- MECHANISMS OF ACTION
- CLINICAL USES OF ANTIDEPRESSANTS
- CHOICE OF AN ANTIDEPRESSANT
- TREATMENT-RESISTANT DEPRESSION
- DEFINITION OF TREATMENT-RESISTANT DEPRESSION
- STAGING MODELS OF TREATMENT-RESISTANT DEPRESSION
- CLINICAL FEATURES ASSOCIATED WITH TREATMENT-RESISTANT DEPRESSION
- CLINICAL APPROACH TO TREATMENT-RESISTANT DEPRESSION
- COMMON TREATMENT STRATEGIES FOR TREATMENT-RESISTANT DEPRESSION
- RESEARCH CHALLENGES
- CONCLUSIONS
- Appendix 1Massachusetts General Hospital Staging Model (MGH-S) definition of TRD – Revised
- REFERENCES
- 4. Lithium and Its Role in Psychiatry
- HISTORICAL CONTEXT
- PHARMACOKINETICS AND PHARMACODYNAMICS
- EVIDENCE FOR LITHIUM’S EFFICACY
- PRINCIPLES OF LITHIUM TREATMENT
- CURRENT CONTROVERSIES AND FUTURE DIRECTIONS
- REFERENCES
- 5. The Use of Antiepileptic Drugs in Psychiatry
- OVERVIEW: HISTORICAL CONTEXT
- PHARMACOKINETICS, PHARMACODYNAMICS, ADVERSE EFFECTS, AND MONITORING
- OTHER ANTICONVULSANTS
- CONCLUSION
- REFERENCES
- 6. The Pharmacotherapy of Anxiety Disorders
- OVERVIEW AND GENERAL PRINCIPLES
- PHARMACOTHERAPY OF PANIC DISORDER AND AGORAPHOBIA
- PHARMACOTHERAPY OF GENERALIZED ANXIETYDISORDER
- PHARMACOTHERAPY OF SOCIAL ANXIETY DISORDER
- CONCLUSIONS AND FUTURE DIRECTIONS
- REFERENCES
- 7. Pharmacotherapy of Attention-Deficit Hyperactivity Disorder Across the Life Span
- OVERVIEW
- STIMULANTS
- ATOMOXETINE
- ALTERNATIVE (NOT APPROVED BY THE FOOD AND DRUG ADMINISTRATION) TREATMENTS FOR ATTENTION-DEFICIT HYPERACTIVITY DISORDER
- SUGGESTED MANAGEMENT STRATEGIES ACROSSTHE LIFE SPAN
- CONCLUSION
- REFERENCES
- 8. Natural Medications in Psychiatry
- OVERVIEW
- EFFICACY AND SAFETY
- MOOD DISORDERS
- ANXIETY AND INSOMNIA
- PREMENSTRUAL AND MENOPAUSAL SYMPTOMS
- COGNITION AND DEMENTIA
- CONCLUSION
- REFERENCES
- 9. Antipsychotic Drugs
- INTRODUCTION
- HISTORY
- GENERAL CLINICAL CONSIDERATIONS
- DRUG SELECTION
- FIRST-GENERATION (“TYPICAL”) ANTIPSYCHOTICS
- EXTRAPYRAMIDAL SYMPTOMS AND TARDIVE DYSKINESIA
- NEUROLEPTIC MALIGNANT SYNDROME
- SECOND-GENERATION (“ATYPICAL”) AND THIRD-GENERATION ANTIPSYCHOTICS
- THIRD-GENERATION AND NEWEST ANTIPSYCHOTICS
- DRUG INTERACTIONS WITH ANTIPSYCHOTIC AGENTS
- ONGOING CHALLENGES
- REFERENCES
- 10. Patients with Abnormal Movements
- OVERVIEW
- IDIOPATHIC MOVEMENT DISORDERS
- TREMORS
- DRUG-INDUCED MOVEMENT DISORDERS
- FUNCTIONAL MOVEMENT DISORDERS
- REFERENCES
- 11. Pathophysiology, Psychiatric Co-morbidity, and Treatment of Pain
- OVERVIEW
- EPIDEMIOLOGY
- PATHOPHYSIOLOGY OF PAIN TRANSMISSION
- CORTICAL SUBSTRATES FOR PAIN AND AFFECT
- INTERACTIONS BETWEEN PAIN AND PSYCHOPATHOLOGY
- PAIN TERMINOLOGY
- ASSESSMENT OF PAIN
- CORE PSYCHOPATHOLOGY AND PAIN-RELATED PSYCHOLOGICAL SYMPTOMS
- PAIN AND CO-MORBID PSYCHIATRIC CONDITIONS
- GENERAL PRINCIPALS OF MULTI-MODAL ANALGESIA
- TREATMENT OF PAIN BEHAVIOR AND THE USE OF MULTI-DISCIPLINARY PAIN CLINICS
- REHABILITATION
- CONCLUSIONS
- REFERENCES
- 12. Psychiatric Illness During Pregnancy and the Post-partum Period
- OVERVIEW
- PRECONCEPTION CONSIDERATIONS
- SCREENING AND DIAGNOSIS OF DEPRESSION AND ANXIETY DURING PREGNANCY
- TREATMENT OF DEPRESSION DURING PREGNANCY: CLINICAL GUIDELINES
- ELECTROCONVULSIVE THERAPY DURING PREGNANCY
- MOOD STABILIZERS DURING PREGNANCY
- TREATMENT OF BIPOLAR DURING PREGNANCY: CLINICAL GUIDELINES
- PSYCHOTIC DISORDERS DURING PREGNANCY
- ANXIETY DISORDERS DURING PREGNANCY
- ATTENTION-DEFICIT HYPERACTIVITY DISORDER AND PREGNANCY
- CANNABIS USE DURING PREGNANCY
- POST-PARTUM MOOD AND ANXIETY DISORDERS: DIAGNOSIS AND TREATMENT
- PREVENTION OF POST-PARTUM PSYCHIATRIC DISORDERS
- BREAST-FEEDING AND PSYCHOTROPIC DRUG USE
- REFERENCES
- 13. Side Effects of Psychotropic Medications
- OVERVIEW
- ANTIDEPRESSANTS
- Tricyclic Antidepressants
- Monoamine Oxidase Inhibitors
- Other Antidepressants
- MOOD STABILIZERS
- ANTIPSYCHOTICS
- ANTI-ANXIETY AND SLEEP AGENTS
- OTHER AGENTS USED IN THE TREATMENT OF PSYCHIATRIC CONDITIONS
- Guanfacine
- REFERENCES
- 14. Drug–Drug Interactions in Psychopharmacology
- OVERVIEW
- CLASSIFICATION
- PHARMACOKINETICS
- ANTIPSYCHOTICS
- MOOD STABILIZERS
- ANTIDEPRESSANTS
- BENZODIAZEPINES
- PSYCHOSTIMULANTS AND MODAFINIL
- REFERENCES
- 15. Pharmacotherapy of Neurocognitive Disorders and Dementia
- OVERVIEW
- EPIDEMIOLOGY OF DEMENTIA
- THE ROLE OF AGE OF ONSET
- EVALUATION OF A PATIENT WITH SUSPECTED COGNITIVE IMPAIRMENT
- ALZHEIMER DISEASE
- LEWY BODY DEMENTIA
- FRONTOTEMPORAL DEMENTIAS
- VASCULAR DEMENTIA
- CORTICOBASAL DEGENERATION
- PROGRESSIVE SUPRANUCLEAR PALSY
- NORMAL-PRESSURE HYDROCEPHALUS
- RAPIDLY PROGRESSING DEMENTIAS: PRION DISEASES WITH CREUTZFELDT–JAKOB DISEASE AS AN EXAMPLE
- CONCLUSIONS
- REFERENCES
- 16. Pharmacotherapy of Substance Use Disorders
- OVERVIEW
- ALCOHOL USE DISORDER AND RELATED CONDITIONS
- COCAINE USE DISORDER AND ASSOCIATED CONDITIONS
- AMPHETAMINE USE DISORDER
- CLUB DRUGS
- OPIOID USE DISORDER AND ASSOCIATED CONDITIONS
- BENZODIAZEPINES AND BARBITURATES
- REFERENCES
- 17. Pharmacotherapy of Sexual Disorders and Sexual Dysfunction
- OVERVIEW
- EPIDEMIOLOGY AND RISK FACTORS
- PATHOPHYSIOLOGY
- CLINICAL FEATURES AND DIAGNOSIS
- DIFFERENTIAL DIAGNOSIS OF SEXUAL DISORDERS
- TREATMENT
- OUTLOOK
- REFERENCES
- 18. Device Neuromodulation and Brain Stimulation Therapies
- OVERVIEW
- TRANSCRANIAL MAGNETIC STIMULATION
- ELECTROCONVULSIVE THERAPY
- VAGUS NERVE STIMULATION
- DEEP BRAIN STIMULATION
- ABLATIVE LIMBIC SYSTEM SURGERY
- Conclusion
- REFERENCES
- 19. Legal Considerations for Mental Health Providers
- OVERVIEW
- BASIC CONCEPTS
- INFORMED CONSENT
- TREATMENT REFUSAL
- CONSENT TO PARTICIPATE IN RESEARCH
- CIVIL COMMITMENT
- THE MEDICAL LIABILITY CLIMATE
- MALPRACTICE LIABILITY
- LIABILITY AND MANAGED CARE
- SELECTED AREAS OF LIABILITY RISK IN PSYCHIATRY
- BOUNDARY VIOLATIONS
- REDUCING MALPRACTICE RISK
- CRIMINAL COMPETENCIES
- COMPETENCY TO PLEAD, DECLINE COUNSEL, AND REPRESENT ONESELF
- COMPETENCY TO BE EXECUTED
- CRIMINAL RESPONSIBILITY
- EVALUATIONS OF CRIMINAL RESPONSIBILITY
- CONCLUSION
- REFERENCES
- Index
- Confidence is ClinicalKey
- Edition: 2
- Published: September 2, 2024
- Imprint: Elsevier
- No. of pages: 256
- Language: English
- Paperback ISBN: 9780443119729
- eBook ISBN: 9780443119736
TS
Theodore A. Stern
Dr. Theodore A. Stern is the Ned H. Cassem Professor of Psychiatry in the field of Psychosomatic Medicine/Consultation at Harvard Medical School (HMS), Chief Emeritus of The Avery D. Weisman, Psychiatry Consultation Service, and Director of the Thomas P. Hackett Center for Scholarship in Psychosomatic Medicine at the Massachusetts General Hospital (MGH). Dr. Stern has co-authored more than 550 peer-reviewed journal articles and book chapters, and he has edited or authored more than 60 books (including the MGH Handbook of General Hospital Psychiatry, the MGH Psychiatry Update and Board Preparation, Learning About Psychopharmacology, Facing Overweight and Obesity, Facing Pelvic Pain, Facing Memory Loss and Dementia, Facing Serious Mental Illness, and the MGH Study Guide for Psychiatry Exams). Dr. Stern is a Past-President of the Academy of Consultation-Liaison Psychiatry (ACLP) and is the Editor-in-Chief Emeritus of its journal, Psychosomatics (now called Journal of the Academy of Consultation-Liaison Psychiatry). He has won the coveted “Best Teacher Award” from the graduating residents at the MGH/McLean Hospital Psychiatric Residency Training Program, the Cynthia N. Kettyle Teaching Award from the HMS Department of Psychiatry, the MGH Department of Psychiatry’s Award for Exceptional Mentorship in the Clinical Realm, a Lifetime Achievement Award from the Society of Liaison Psychiatry, and the Thomas P. Hackett Award from the ACLP (its highest honor).
Affiliations and expertise
Psychiatrist and Chief Emeritus, Avery D. Weisman Psychiatry Consultation Service, Director, Thomas P. Hackett Center for Scholarship in Psychosomatic Medicine, Massachusetts General Hospital, Boston, MA, USA, Ned H. Cassem Professor of Psychiatry in the Field, Psychosomatic Medicine/Consultation, Harvard Medical School, Boston, MA, USAJC
Joan A. Camprodon
Dr. Joan A. Camprodon is board-certified in Psychiatry, and Behavioral Neurology & Neuropsychiatry. His research (as Director of the Laboratory for Neuropsychiatry and Neuromodulation) uses multimodal combinations of neuroimaging and brain stimulation to investigate neural circuitry and plasticity in a translational manner. His lab works with a wide range of noninvasive and invasive neuromodulation techniques including transcranial electrical current stimulation (tECS), transcranial magnetic stimulation (TMS), electroconvulsive therapy (ECT) and deep brain stimulation (DBS) among others. The scope of his research includes basic, translational and clinical projects focused on circuit neuroscience.
Affiliations and expertise
Chief, Division of Neuropsychiatry, Massachusetts General Hospital, Director, Laboratory for Circuit Neuroscience and Neuromodulation, Massachusetts General Hospital, Director, Transcranial Magnetic Stimulation Clinical Service, Psychiatry, Massachusetts General Hospital, Boston, MA, USA, Associate Professor of Psychiatry, Harvard Medical School, Boston, MA, USAMF
Maurizio Fava
Dr. Maurizio Fava is Chair of the Department of Psychiatry at the Massachusetts General Hospital (MGH). Dr. Fava obtained his MD from University of Padova School of Medicine (residency in endocrinology); he completed residency training in psychiatry at the MGH. He founded and was director of the hospital’s Depression Clinical and Research Program (DCRP) from 1990 to 2014. In 2007, he founded and is now Executive Director of the MGH Clinical Trials Network and Institute (CTNI), the first academic CRO specialized in planning and coordination of multi-center clinical trials in psychiatry. Under Dr. Fava’s direction, the DCRP became one of the most highly regarded depression programs in the country, a model for academic programs that link, in a bi-directional fashion, clinical and research work. His prominence in the field is reflected in his role as the co-principal investigator of STAR*D, the largest research study ever conducted in the area of depression, and of the RAPID Network, the NIMH-funded series of studies of novel, rapidly acting antidepressant therapies. Dr. Fava is a world leader in the field of depression. He has authored or co-authored more than 900 original articles published in medical journals with international circulation, edited eight books, and has been successful in obtaining funding as principal or co-principal investigator from both the National Institutes of Health and other sources for a total of more than $150 million.
Affiliations and expertise
Psychiatrist-in-Chief, Department of Psychiatry, Vice Chair, Executive Committee on Research, Massachusetts General Hospital, Boston, MA, USA, Executive Director, Clinical Trials Network & Institute (CTNI), Massachusetts General Hospital, Boston, MA, USA, Associate Dean for Clinical & Translational Research & Slater Family Professor of Psychiatry, Harvard Medical School, Boston, MA, USARead Massachusetts General Hospital Psychopharmacology and Neurotherapeutics on ScienceDirect